Andrew J. Yee

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 655 citations · Full text

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Paul G. Richardson, Susanna Jacobus, Edie Weller et al. · New England Journal of Medicine · 2022 · 428 citations · Full text

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

Frataxin activates mitochondrial energy conversion and oxidative phosphorylation

Michael Ristow, M. Pfister, Andrew J. Yee et al. · Proceedings of the National Academy of Sciences · 2000 · 222 citations

Reductive Stress, Mitophagy, Signal Transduction +11